TrialNeurology2021

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.

Vera Bril et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.